JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Item
http://www.wikidata.org/entity/Q45797468
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 MutationDetection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay.Identification of AIM2 as a downstream target of JAK2V617F.JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients.JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria.Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
P2860

JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Item
http://www.wikidata.org/entity/Q45797468
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@en
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@nl
type
label
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@en
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@nl
prefLabel
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@en
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698
P356
P1433
P1476
JAK2V617F mutation status and ...... liferative neoplasms in Japan.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698